Patent grant sees Novogen shares soar
14 January, 2003 by Melissa TrudingerNovogen's share price jumped more than 11 per cent to $3.81 yesterday after the company announced that an Australian patent had been granted for its topical skin repair treatment NV-07a.
Boron Molecular completes capital raising, considers IPO
10 January, 2003 by Melissa TrudingerBoron Molecular, a small Melbourne-based medicinal chemistry company, is planning to pursue listing on the Australian Stock Exchange in the next six months if market conditions are favourable, according to managing director Dr Phillip Reese.
Gene technology to be used in carp control plan
10 January, 2003 by Graeme O'NeillThe Murray-Darling Basin Commission is to back a radical new attempt to control Australia's worst aquatic pest, the carp.
Peptech reaps $10m from share placement
09 January, 2003 by Graeme O'NeillSydney-based biotechnology company Peptech Limited today announced it has raised $AUD10 million in new capital by placing 6,625,000 shares with several major institutions, including AMP, ING Australia and the Escor Group.
Door opens for Ventracor clinical trials
09 January, 2003 by Melissa TrudingerVentracor has gained approval from the Alfred Hospital's Ethics Committee, paving the way for the first clinical trial of its VentrAssist artificial heart device to begin.
Autogen eyes global market after capital raising
08 January, 2003 by Melissa TrudingerMelbourne-based biotech Autogen plans to spend the proceeds of a $AUD6.65 million capital raising on expanding globally, including upgrading a level 1 American Depositary Receipt (ADR) Nasdaq listing to a level 2 ADR listing during the coming year and actively seeking new partners and possible acquisitions.
Greenpeace to step up fight against GM canola in Australia
08 January, 2003 by Graeme O'NeillGreenpeace Australia Pacific has signalled that it will step up its campaign to block the introduction of genetically modified canola into Australia, by advertising for a new anti-GM campaigner.
Scale-up problems force layoffs at Ambri
08 January, 2003 by Pete YoungListed biotech Ambri Ltd has laid off 15 staff in response to unexpected manufacturing problems in scaling up its biosensor technology for commercial production.
Research points the whey forward for milk
20 December, 2002 by Graeme O'NeillMilk is the first food that any mammal tastes, a fluid perfectly formulated by nature for the nutritional and developmental needs of newborn mammals.
Biotech's six million dollar woman
20 December, 2002 by Pete YoungA young biotech that is developing technology to improve racehorse performance is easily outpacing the field when it comes to attracting development funding.
ESI gets rights to diabetes technology
19 December, 2002 by Melissa TrudingerSingapore-based stem cell company ES Cell International (ESI) has acquired patent rights to technology relating to the transformation of stem cells into insulin-producing cells from US company Curis.
Local biotechs unhappy with ASIC report
19 December, 2002 by Pete YoungA number of listed biotechs named by the Australian Securities and Investments Commission (ASIC) as facing potential solvency problems are crying foul.
US maize shipments tipped to to raise anti-GM hackles
18 December, 2002 by Graeme O'NeillAs a desperate measure to keep alive elite dairy and beef cattle herds suffering in one of the worst droughts of the past century, Australia's livestock industries are moving to ship in maize from the US.
Genetraks raises $6m
18 December, 2002 by Pete YoungGenetraks, a start-up biotech developing blood tests for use in pre-race evaluation of animals such as racehorses, has received a $6 million injection of venture capital.
INTERVIEW: The Andrews view: hang on for a big 2003
17 December, 2002 by Pete YoungThe biotech shake-up will intensify in 2003 but the horizon looks inviting on the far side of the wave of mergers expected to roll through the sector over the next 12 to 24 months. That's the view of Prof Peter Andrews, a leading member of the generation which has dramatically reshaped Australian bioscience in the last 15 years and a man who boasts a good track record in sculpting positive environments for young biotechs.
